featured
Neoadjuvant and Adjuvant Pembrolizumab Plus Chemotherapy for Locally Advanced Gastric or Gastro-Oesophageal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Lancet Oncol 2023 Dec 19;[EPub Ahead of Print], K Shitara, SY Rha, LS Wyrwicz, T Oshima, N Karaseva, M Osipov, H Yasui, H Yabusaki, S Afanasyev, YK Park, SE Al-Batran, T Yoshikawa, P Yanez, M Dib Bartolomeo, S Lonardi, J Tabernero, E Van Cutsem, YY Janjigian, DY Oh, J Xu, X Fang, CS Shih, P Bhagia, YJ BangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.